Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects murine bone marrow–derived cells with features of mesenchymal stem cells
Corresponding Author
Larisa Cervenakova
Larisa Cervenakova, Transmissible Diseases Department, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855; e-mail: [email protected].Search for more papers by this authorSergey Akimov
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorIrina Vasilyeva
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorOksana Yakovleva
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorCarroll McKenzie
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorJuraj Cervenak
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorPedro Piccardo
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorDavid M. Asher
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorCorresponding Author
Larisa Cervenakova
Larisa Cervenakova, Transmissible Diseases Department, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855; e-mail: [email protected].Search for more papers by this authorSergey Akimov
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorIrina Vasilyeva
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorOksana Yakovleva
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorCarroll McKenzie
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorJuraj Cervenak
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorPedro Piccardo
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorDavid M. Asher
From the Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland; the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents, DETTD, OBRR, CBER, US Food and Drug Administration (FDA), Kensington, Maryland; and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Search for more papers by this authorSome cell culture studies were supported in part by an interagency transfer of funds to the FDA from NIAID, NIH.
The findings and conclusions in this article have not been formally disseminated by the FDA and should not be construed to represent any Agency determination or policy.
Abstract
BACKGROUND: The possible risk of iatrogenic transmissible spongiform encephalopathies (TSEs, prion diseases) from transplantation of marrow-derived mesenchymal stem cells (MSCs) is uncertain. While most cell lines resist infection, a few propagate TSE agents.
STUDY DESIGN AND METHODS: We generated MSC-like (MSC-L) cell cultures from bone marrow (BM) of mice inoculated with the human-derived Fukuoka-1 (Fu) strain of TSE agent. Cultured cells were characterized for various markers and cellular prion protein (PrPC) by fluorescence-activated cell sorting and for PrPC and its pathologic TSE-associated form (PrPTSE) by Western blotting (WB). Cell cultures were tested for their susceptibility to infection with Fu in vitro. The infectivity of one Fu-infected cell culture was assayed in mice.
RESULTS: BM cells from Fu-infected mice expressed neither PrPC nor PrPTSE after 3 days in culture as demonstrated by WB. Cells adherent to plastic and maintained under two different culture conditions became spontaneously immortalized and began to express PrPC at about the same time. One culture became transformed shortly after exposure to Fu in vitro and remained persistently infected, continuously generating PrPTSE through multiple passages; the infectivity of cultured cells was confirmed by intracerebral inoculation of lysates into mice. Both persistently TSE-infected and uninfected cells expressed a number of typical MSC markers.
CONCLUSION: BM-derived MSC-L cells of mice became persistently infected with the Fu agent under certain conditions in culture—conditions that differ substantially from those currently used to develop investigational human stem cell therapies.
REFERENCES
- 1 Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that “new variant” CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
- 2 Brown P, Brandel JP, Preece M, Sato M. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67: 389-93. Epub (2006 Jul 19). Erratum in: Neurology 2006; 67:1528. Preese, Michael (corrected to Preece, Michael).
- 3 Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion medicine epidemiological review study. Vox Sang 2006; 91: 221-30.
- 4 Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304. Epub 2010 Jan 12.
- 5 Dorsey K, Zou S, Schonberger KB, Sullivan M, Kessler D, Notari E 4th, Fang CT, Dodd RY. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009; 49: 977-84. Epub 2009 Jan 5.
- 6 Manuelidis EE, Kim JH, Mericangas JR, Manuelidis L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985; 2: 896-7.
- 7 Tamai Y, Kojima H, Kitajima R, Taguchi F, Ohtani Y, Kawaguchi T, Miura S, Sato M, Ishihara Y. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease. N Engl J Med 1992; 327: 649.
- 8 Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001; 137: 5-15.
- 9 Grassi J, Maillet S, Simon S, Morel N. Progress and limits of TSE diagnostic tools. Vet Res 2008; 39: 3.
- 10 Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70: 1272-81. Review.
- 11 Manuelidis L, Liu Y, Mullins B. Strain-specific viral properties of variant Creutzfeldt-Jakob disease (vCJD) are encoded by the agent and not by host prion protein. J Cell Biochem 2009; 106: 220-31.
- 12 Prusiner SB. Molecular biology of prion diseases. Science 1991; 252: 1515-22.
- 13 World Health Organization. WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. WHO Press; 2006. 26 pp. [cited 2011 Jan 13]. Available from: URL: http://www.who.int/bloodproducts/cs/TSEPUBLISHEDREPORT.pdf
- 14 Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987; 51: 229-40.
- 15 Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, Kascsak RJ, Cashman NR, Bolton DC. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 1992; 42: 149-56.
- 16 Horiuchi M, Yamazaki N, Ikeda T, Ishiguro N, Shinagawa M. A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 1995; 76: 2583-7.
- 17 Weissmann C, Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Br Med Bull 2003; 66: 43-60. Review.
- 18 Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J, Kato S, Ishida I, Soto C, Robl JM, Kuroiwa Y. Production of cattle lacking prion protein. Nat Biotechnol 2007; 25: 132-8. Epub 2006 Dec 31.
- 19 Vilette D. Cell models of prion infection. Vet Res 2008; 39: 10.
- 20 Kocisko DA, Caughey B. Searching for anti-prion compounds: cell-based high-throughput in vitro assays and animal testing strategies. Methods Enzymol 2006; 412: 223-34.
- 21 Mahal SP, Demczyk CA, Smith EW Jr, Klohn PC, Weissmann C. Assaying prions in cell culture: the standard scrapie cell assay (SSCA) and the scrapie cell assay in end point format (SCEPA). Methods Mol Biol 2008; 459: 49-68.
- 22 Akimov S, Yakovleva O, Vasilyeva I, McKenzie C, Cervenakova L. Persistent propagation of variant Creutzfeldt-Jakob disease agent in murine spleen stromal cell culture with features of mesenchymal stem cells. J Virol 2008; 82: 10959-62.
- 23 Akimov S, Vasilyeva I, Yakovleva O, McKenzie C, Cervenakova L. Murine bone marrow stromal cell culture with features of mesenchymal stem cells susceptible to mouse-adapted human TSE agent, Fukuoka-1. Folia Neuropathol 2009; 47: 205-14.
- 24 Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-5.
- 25 Tateishi J, Ohta M, Koga M, Sato Y, Kuroiwa Y. Transmission of chronic spongiform encephalopathy with kuru plaques from humans to small rodents. Ann Neurol 1979; 5: 581-4.
- 26 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
- 27 Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr Opin Oncol 2007; 19: 650-5.
- 28 Granero-Molto F, Weis JA, Longobardi L, Spagnoli A. Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair. Expert Opin Biol Ther 2008; 8: 255-68.
- 29 Gastens MH, Goltry K, Prohaska W, Tschöpe D, Stratmann B, Lammers D, Kirana S, Götting C, Kleesiek K. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant 2007; 16: 685-96.
- 30 Dennis JE, Esterly K, Awadallah A, Parrish CR, Poynter GM, Goltry KL. Clinical-scale expansion of a mixed population of bone-marrow-derived stem and progenitor cells for potential use in bone-tissue regeneration. Stem Cells 2007; 25: 2575-82.
- 31 Ponzio NM, Brown PH, Thorbecke GJ. Host-tumor interactions in the SJL lymphoma model. Int Rev Immunol 1986; 1: 273-301.
- 32 Tang JC, Ho FC, Chan AC, Srivastava G. Clonality of lymphomas at multiple sites in SJL mice. Lab Invest 1998; 78: 205-12.
- 33 Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988; 18: 97-104.
- 34 Vorberg I, Priola SA. Molecular basis of scrapie strain glycoform variation. J Biol Chem 2002; 277: 36775-81.
- 35 Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004; 103: 1662-8.
- 36 Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43: 1687-94.
- 37 Cervenakova L, Yakovleva O, McKenzie C. Protease-resistant prion protein in lymphoreticular tumors of variant Creutzfeldt-Jakob disease mice. Emerg Infect Dis 2006; 12: 511-3.
- 38 Reed LJ, Muench H. A simple method of estimating fifty percent end points. Am J Hyg 1938; 27: 493-7.
- 39 Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A 2007; 104: 4712-7.
- 40 Markovits P, Dautheville C, Dormont D, Dianoux L, Latarjet R. In vitro propagation of the scrapie agent. I. Transformation of mouse glia and neuroblastoma cells after infection with the mouse-adapted scrapie strain c-506. Acta Neuropathol 1983; 60: 75-80.
- 41 Oleszak EL, Manuelidis L, Manuelidis EE. In vitro transformation elicited by Creutzfeldt-Jakob-infected brain material. J Neuropathol Exp Neurol 1986; 45: 489-502.
- 42 Manuelidis EE, Fritch WW, Kim JH, Manuelidis L. Immortality of cell cultures derived from brains of mice and hamsters infected with Creutzfeldt-Jakob disease agent. Proc Natl Acad Sci U S A 1987; 84: 871-5.
- 43 Takakura Y, Yamaguchi N, Nakagaki T, Satoh K, Kira J, Nishida N. Bone marrow stroma cells are susceptible to prion infection. Biochem Biophys Res Commun 2008; 377: 957-61.
- 44 Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-29.
- 45 Frazer H, Foster J. Transmission to mice, sheep and goats and bioassay of bovine tissues. In: R Bradley, B Marchant, editors. Transmissible spongiform encephalopathies. A consultation on BSE with the Scientific Veterinary Committee of the Comission of the European Communities held in Brussels, September 14-15, 1993. Document VI/4131/94-EN. Brussels: European Commision Agriculture; 1994. p. 145-59.
- 46 Bradley R. The research programme on transmissible spongiform encephalopathies in Britain with special reference to bovine spongiform encephalopathy. Dev Biol Stand 1993; 80: 157-70.
- 47 Bradley R. BSE transmission studies with particular reference to blood. Dev Biol Stand 1999; 99: 35-40.
- 48 Sohn HJ, Lee YH, Green RB, Spencer YI, Hawkins SA, Stack MJ, Konold T, Wells GA, Matthews D, Cho IS, Joo YS. Bone marrow infectivity in cattle exposed to the bovine spongiform encephalopathy agent. Vet Rec 2009; 164: 272-3.
- 49 Wells GA, Hawkins SA, Green RB, Spencer YI, Dexter I, Dawson M. Limited detection of sternal bone marrow infectivity in the clinical phase of experimental bovine spongiform encephalopathy (BSE). Vet Rec 1999; 144: 292-4.
- 50 Eklund CM, Kennedy RC, Hadlow WJ. Pathogenesis of scrapie virus infection in the mouse. J Infect Dis 1967; 117: 15-22.
- 51 Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis 1982; 146: 657-64.
- 52 Hadlow WJ, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy goats affected with natural scrapie. Vet Pathol 1980; 17: 187-99.
- 53 Hadlow WJ, Eklund CM, Kennedy RC, Jackson TA, Whitford HW, Boyle CC. Course of experimental scrapie virus infection in the goat. J Infect Dis 1974; 129: 559-67.
- 54 Caplazi P, O'Rourke K, Wolf C, Shaw D, Baszler TV. Biology of PrPsc accumulation in two natural scrapie-infected sheep flocks. J Vet Diagn Invest 2004; 16: 489-96.
- 55 Manuelidis EE, Gorgacz EJ, Manuelidis L. Viremia in experimental Creutzfeldt-Jakob disease. Science 1978; 200: 1069-71.
- 56 Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-61.
- 57 Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6.
- 58 Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
- 59 Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
- 60 Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83(Pt 11): 2897-905.
- 61 Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, Sisó S, González L, Jeffrey M, Hunter N. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008; 112: 4739-45.
- 62 Taylor DM, Fernie K, Reichl HE, Somerville RA. Infectivity in the blood of mice with a BSE-derived agent. J Hosp Infect 2000; 46: 78-9.
- 63 Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364: 529-31.
- 64 Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368: 2226-30.
- 65 Gillies M, Chohan G, Llewelyn CA, Mackenzie J, Ward H, Hewitt PE, Will RG. A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions. Vox Sang 2009; 97: 211-8. Epub 2009 Aug 6.
- 66 Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339-47.
- 67 Charbord P, Oostendorp R, Pang W, Hérault O, Noel F, Tsuji T, Dzierzak E, Péault B. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissues. Exp Hematol 2002; 30: 1202-10.
- 68 Tropel P, Platet N, Platel JC, Noël D, Albrieux M, Benabid AL, Berger F. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 2868-76.
- 69 Vogel W, Grünebach F, Messam CA, Kanz L, Brugger W, Bühring HJ. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica 2003; 88: 126-33.
- 70 Scott M, Peretz D, Ridley RM, Baker HF, DeArmond SJ, Prusiner SB. Transgenic investigations of species barrier and prion strains. In: SB Prusiner, editor. Prion biology and diseases. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2004. p. 435-82.
- 71 Arima K, Nishida N, Sakaguchi S, Shigematsu K, Atarashi R, Yamaguchi N, Yoshikawa D, Yoon J, Watanabe K, Kobayashi N, Mouillet-Richard S, Lehmann S, Katamine S. Biological and biochemical characteristics of prion strains conserved in persistently infected cell cultures. J Virol 2005; 79: 7104-12.
- 72 Zhang CC, Steele AD, Lindquist S, Lodish HF. Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc Natl Acad Sci U S A 2006; 103: 2184-9.
- 73 Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 2005; 105: 4314-20.
- 74 World Health Organization. WHO guidelines on transmissible spongiform encephalopathies in relation to biological and pharmaceutical products. 2003. [cited 2011 Jan 13]. Available from: URL: http://whqlibdoc.who.int/hq/2003/a85721.pdf
Citing Literature
